FDA inspection classifications: NAI, VAI, and OAI for pharmacy research

01

How FDA reaches a final inspection classification

An investigator can issue a Form FDA 483 at the end of an inspection when observed conditions may constitute violations. The facility may respond with corrections and supporting information. FDA then evaluates the inspection evidence, the response, applicable requirements, risk, and other information before assigning a final classification.

FDA says the investigator's recommendation is important but not the only factor. The agency can consider proposed or completed corrective actions. That is why a 483 and a classification answer different questions and may be posted at different times.

For human drug CGMP inspections, FDA says it strives to complete classification within 90 days after the inspection ends and generally posts the result to its dashboard. Timing can vary, and a public record may lag the underlying activity.

02

NAI: no action indicated

FDA defines NAI as no objectionable conditions or practices found during the inspection. Its pharmaceutical-inspection page says the facility usually was not issued a Form 483. NAI is the least concerning of the three classifications for that inspection.

Do not translate NAI into FDA approved, perfect, sterile, or safe for every product. The classification is limited to the inspected facility, dates, scope, and evidence. A later event, different site, uninspected operation, shipping problem, or individual batch may raise separate issues.

For provider research, record NAI with the inspection end date and program area. Look for later inspections, recalls, warning letters, and state actions. A favorable older record should not hide a newer adverse one, and a favorable record at one location should not be transferred to an affiliated location.

03

VAI: voluntary action indicated

FDA defines VAI as objectionable conditions or practices found, but the agency is not prepared to take or recommend administrative or regulatory action. The facility usually received a Form 483. The expectation is voluntary correction.

VAI is not a clean inspection and should not be described as passed without findings. At the same time, it is not OAI and should not be reported as shutdown, enforcement, or a final finding that every observation violated the law.

Read the observations and facility response when available. Ask whether corrective actions were completed and whether a later inspection tested them. A provider citing only the absence of a warning letter leaves out the VAI findings. The same principle applies when marketing says FDA found no official action was necessary without disclosing the objectionable conditions.

04

OAI: official action indicated

FDA defines OAI as a classification in which regulatory or administrative actions are recommended. For human drug CGMP inspections, FDA describes OAI as an unacceptable state of compliance. Possible consequences can include a warning letter, import action, seizure, injunction, or effects on pending applications, depending on the facts and authority.

OAI does not mean every possible enforcement action occurred, that the facility closed, or that every product caused harm. Use the classification as a serious signal, then identify the actual action and product scope from primary records.

FDA says an OAI drug CGMP classification generally changes only after comprehensive corrective and preventive actions are implemented and verified through an onsite follow-up inspection. Check for later classifications and closeout records rather than assuming either permanent failure or automatic resolution.

05

Search the correct facility and inspection

Use the legal facility name, physical address, and FDA establishment identifier when available. Similar company names, parent companies, affiliates, and multiple locations can produce false matches. A pharmacy brand used by a clinic may not be the inspected legal entity.

FDA's inspection-classification database covers final classifications for inspections related to currently marketed regulated products, but FDA notes exclusions. State-conducted inspections, preapproval inspections, and inspections awaiting certain final actions may not appear. No result must therefore be labeled no public FDA classification found, not never inspected.

Capture the inspection dates, project area, classification, and access date. Follow links to 483s, warning letters, recalls, import alerts, and later inspections where available. Then check the applicable state pharmacy license because federal inspection data do not replace state oversight.

• →Legal name and physical site
• →Inspection start and end dates
• →Program or project area
• →Final NAI, VAI, or OAI classification
• →Form 483 and facility response
• →Later FDA inspection or enforcement
• →State license, discipline, and recalls

06

How to describe a classification without overclaiming

Use a dated sentence: FDA classified the facility's inspection ending on a specific date as VAI. Then define VAI in FDA's terms. Avoid letter grades, pass-fail language, or a general safety score that the agency does not use.

State important limitations near the result. A classification does not approve a facility or compounded product, establish treatment effectiveness, or guarantee future compliance. A 503B facility may have federal inspection records, while a 503A pharmacy's most relevant public inspection or discipline record may be at the state level.

If a provider markets NAI as a permanent FDA certification or omits a newer OAI classification, request clarification and preserve the source. If an OAI record is old and later correction is verified, include the later record just as prominently. Fair research is both skeptical and current.